EMA Says Yes To PRIME Designations For Wet AMD & HAE Gene Therapies

 
• By Neena Brizmohun
  
Generate a summary of this article
Listen to this article
Beta

Two gene therapies, from Molecular Therapeutics and Intellia Therapeutics respectively, are among the four new products the European Medicines Agency accepted onto it priority medicines scheme this month.

gene and color background
Two new gene therapy candidates have won PRIME designation • Source: Shutterstock

NTLA-2002 and 4D-150, which are single-dose, gene therapy candidates for hereditary angioedema and neovascular age-related macular degeneration (wet AMD) respectively, are among the latest products to be accepted onto PRIME, the European Medicines Agency’s priority medicines scheme for drugs for unmet medical needs.

Key Takeaways

  • Two gene therapies and two biological drugs were accepted onto the European Medicines Agency’s PRIME scheme in October, and three applications for PRIME designation were rejected.

NTLA-2002, from Intellia Therapeutics, and 4D-150, from Molecular Therapeutics, were among four investigational products that secured a PRIME...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Europe

EU Biosimilar Filings, Opinions And Approvals

 
• By Saba Afreen

<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

EU Pharma Reform: What You Need to Know Now

 
• By Anabel Costa-Ferreira and Ian Schofield

As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

New EU Approvals

<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography

Canada Cuts Red Tape With Single Ethics Review For Trials

A new research ethics review system for multi-site clinical trials in Canada is expected to help improve study start-up times, avoid unnecessary duplication and boost the country’s competitiveness on a global stage.

Nancy Test Circulable Section Geography

 
• By Brian Bossetta

This is a short description

Diversity Action Plans: What To Submit And When

 
• By Nielsen Hobbs

With the deadline for comments on the US FDA’s draft guidance less than a month away, the Pink Sheet offers an infographic outlining what the agency is expecting in diversity action plans and when that might be implemented.